Tenaya Therapeutics, Inc. Common Stock
Here’s whether Tenaya Therapeutics, Inc. Common Stock (TNYA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 63 — healthy momentum range; strong 1-year return of +69.3%; 3-month momentum positive (+7.2%). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-1.46% over 10 days); declining volume on rally — weak conviction (0.79x 30d avg). Currently 66.7% off its 52-week high. Score: +0/7.
TNYA is trading below its 200-day MA ($1.02) — a key warning sign the longer-term trend is under pressure. An RSI of 63.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +69.3% compares to +35.1% for SPY (beat the market by 34.2%). The current 66.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.